Status: Not yet recruiting
UGX202 Injection in Patients With Advanced Retinitis Pigmentosa
The primary objective of this clinical trial is to evaluate the safety and tolerability of a single intravitreal injection of the gene therapy drug UGX202 in patients with advanced RP. The secondary objective is, to assess the preliminary efficacy of a single intravitreal injection of the gene therapy drug UGX202 in treating patients with advanced RP.
Participants needed: 6
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Suzhou UgeneX Therapeutics Co., Ltd.Updated: Dec 31, 2025Locations: 1
Eligibility criteria
Provide written informed consent form (ICF). [+5]
Prior gene therapy in either eye. [+5]